WallStreetZenWallStreetZen

NASDAQ: TRDA
Entrada Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for TRDA

Based on 2 analysts offering 12 month price targets for Entrada Therapeutics Inc.
Min Forecast
$20.00+45.67%
Avg Forecast
$21.00+52.95%
Max Forecast
$22.00+60.23%

Should I buy or sell TRDA stock?

Based on 2 analysts offering ratings for Entrada Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their TRDA stock forecasts and price targets.

TRDA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-01-05
lockedlocked$00.00+00.00%2023-11-27

1 of 1

Forecast return on equity

Is TRDA forecast to generate an efficient return?

Forecast return on assets

Is TRDA forecast to generate an efficient return on assets?

TRDA revenue forecast

What is TRDA's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$88.8M+1.88%
Avg 2 year Forecast
$35.7M-59.03%
Avg 3 year Forecast
$108.2M+24.14%
TRDA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TRDA revenue growth forecast

How is TRDA forecast to perform vs Biotechnology companies and vs the US market?
Company
-0.43%
Industry
45.89%
Market
10.82%
TRDA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TRDA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TRDA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TRDA$13.73$21.00+52.95%Buy
STTK$9.65$20.00+107.25%Buy
TNYA$6.67$12.50+87.41%Buy
OCS$12.00$30.75+156.25%Strong Buy
TERN$7.31$10.83+48.19%Buy

Entrada Therapeutics Stock Forecast FAQ

Is Entrada Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: TRDA) stock is to Buy TRDA stock.

Out of 2 analysts, 0 (0%) are recommending TRDA as a Strong Buy, 2 (100%) are recommending TRDA as a Buy, 0 (0%) are recommending TRDA as a Hold, 0 (0%) are recommending TRDA as a Sell, and 0 (0%) are recommending TRDA as a Strong Sell.

If you're new to stock investing, here's how to buy Entrada Therapeutics stock.

What is TRDA's revenue growth forecast for 2024-2026?

(NASDAQ: TRDA) Entrada Therapeutics's forecast annual revenue growth rate of -0.43% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.89%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.82%.

Entrada Therapeutics's revenue in 2024 is $87,165,000.On average, 3 Wall Street analysts forecast TRDA's revenue for 2024 to be $2,963,285,535, with the lowest TRDA revenue forecast at $1,882,626,961, and the highest TRDA revenue forecast at $4,337,850,140. On average, 2 Wall Street analysts forecast TRDA's revenue for 2025 to be $1,191,574,065, with the lowest TRDA revenue forecast at $500,521,170, and the highest TRDA revenue forecast at $1,882,626,961.

In 2026, TRDA is forecast to generate $3,610,759,720 in revenue, with the lowest revenue forecast at $1,882,626,961 and the highest revenue forecast at $5,338,892,480.

What is TRDA's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: TRDA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is TRDA's Price Target?

According to 2 Wall Street analysts that have issued a 1 year TRDA price target, the average TRDA price target is $21.00, with the highest TRDA stock price forecast at $22.00 and the lowest TRDA stock price forecast at $20.00.

On average, Wall Street analysts predict that Entrada Therapeutics's share price could reach $21.00 by Jan 5, 2025. The average Entrada Therapeutics stock price prediction forecasts a potential upside of 52.95% from the current TRDA share price of $13.73.

What is TRDA's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: TRDA) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.